Featured
Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib
Read More →
Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA
Read More →
FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials
Read More →
FDA Grants Rare Pediatric Disease Designation (RPDD) to dovitinib for osteosarcoma
Read More →
Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas
Read More →
Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib
Read More →
Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy
Read More →
SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers
Read More →
Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA
Read More →
FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma
Read More →